Dr. Rana McKay

everybody does it different, every doc doesn't different, there isn't sort of like a system. So I think like kind of being a little bit more systematic about, you know, these are the options that you have.

everybody does it different, every doc doesn't different, there isn't sort of like a system. So I think like kind of being a little bit more systematic about, you know, these are the options that you have.

everybody does it different, every doc doesn't different, there isn't sort of like a system. So I think like kind of being a little bit more systematic about, you know, these are the options that you have.

And these are the side effects, you know, at our institution, a DTF kind of we piloted together kind of like an ADT order set, you know, like when you're going to start ADT, these are the things to think of, these are the labs to think of, this is the imaging, here's the teaching. And I think that that really kind of takes out a lot of bias from the process.

And these are the side effects, you know, at our institution, a DTF kind of we piloted together kind of like an ADT order set, you know, like when you're going to start ADT, these are the things to think of, these are the labs to think of, this is the imaging, here's the teaching. And I think that that really kind of takes out a lot of bias from the process.

And these are the side effects, you know, at our institution, a DTF kind of we piloted together kind of like an ADT order set, you know, like when you're going to start ADT, these are the things to think of, these are the labs to think of, this is the imaging, here's the teaching. And I think that that really kind of takes out a lot of bias from the process.

So I think standardization is important and also kind of seeing what the goals are for the patient and aligning with them is really key.

So I think standardization is important and also kind of seeing what the goals are for the patient and aligning with them is really key.

So I think standardization is important and also kind of seeing what the goals are for the patient and aligning with them is really key.

I'm doing great. Thanks for having me.

I'm doing great. Thanks for having me.

I'm doing great. Thanks for having me.

Yeah, I mean, absolutely. I think, you know, androgen deprivation therapy has been the backbone of systemic treatment for patients with prostate cancer for decades, has been and will likely continue to be just given the addiction of prostate cancer to the androgen receptor and androgen receptor signaling pathway.

Yeah, I mean, absolutely. I think, you know, androgen deprivation therapy has been the backbone of systemic treatment for patients with prostate cancer for decades, has been and will likely continue to be just given the addiction of prostate cancer to the androgen receptor and androgen receptor signaling pathway.

Yeah, I mean, absolutely. I think, you know, androgen deprivation therapy has been the backbone of systemic treatment for patients with prostate cancer for decades, has been and will likely continue to be just given the addiction of prostate cancer to the androgen receptor and androgen receptor signaling pathway.

And I think there's been definitely an evolution over the last several decades in how we facilitate a medical decline in testosterone levels with a therapeutic intent to treat prostate cancer. Historically, before we had GnRH analogs, we just used good old bilateral orchiectomy to treat patients.

And I think there's been definitely an evolution over the last several decades in how we facilitate a medical decline in testosterone levels with a therapeutic intent to treat prostate cancer. Historically, before we had GnRH analogs, we just used good old bilateral orchiectomy to treat patients.

And I think there's been definitely an evolution over the last several decades in how we facilitate a medical decline in testosterone levels with a therapeutic intent to treat prostate cancer. Historically, before we had GnRH analogs, we just used good old bilateral orchiectomy to treat patients.

And, you know, there's still a role for that even in the modern era, if you will, if we think about the cost of care and in people who are going to be on indefinite ADT without any reason to discontinue therapy, it still plays a role in the modern era for a select number of patients.

And, you know, there's still a role for that even in the modern era, if you will, if we think about the cost of care and in people who are going to be on indefinite ADT without any reason to discontinue therapy, it still plays a role in the modern era for a select number of patients.